|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/21/24 Xenetic Biosciences, Inc. 10-K 12/31/23 71:5.6M GlobalOne Filings Inc/FA |
Document/Exhibit Description Pages Size
1: 10-K Form 10-K for Dec 2023 HTML 1.32M
2: EX-4.1 Description of Registrants Securities Registered HTML 31K
Pursuant to Section 12 of the Securities Exchange
Act of 1934
3: EX-21.1 Subsidiaries List HTML 19K
4: EX-23.1 Consent of Marcum LLP HTML 19K
8: EX-97.1 Policy Regarding the Mandatory Recovery of HTML 34K
Compensation
5: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
14: R1 Cover HTML 94K
15: R2 Consolidated Balance Sheets HTML 102K
16: R3 Consolidated Balance Sheets (Parenthetical) HTML 42K
17: R4 Consolidated Statements of Comprehensive Loss HTML 62K
18: R5 Consolidated Statements of Comprehensive Loss HTML 37K
(Parenthetical)
19: R6 Consolidated Statements of Stockholders' Equity HTML 60K
20: R7 Consolidated Statements of Cash Flows HTML 74K
21: R8 Pay vs Performance Disclosure HTML 32K
22: R9 Insider Trading Arrangements HTML 26K
23: R10 The Company HTML 28K
24: R11 Risks and Uncertainties HTML 23K
25: R12 Summary of Significant Accounting Policies HTML 74K
26: R13 Significant Strategic Collaborations HTML 42K
27: R14 Licensing Arrangements HTML 36K
28: R15 Other Assets HTML 24K
29: R16 Accrued Expenses HTML 27K
30: R17 Fair Value Measurements HTML 26K
31: R18 Income Taxes HTML 74K
32: R19 Stockholders? Equity HTML 60K
33: R20 Share-Based Expense HTML 122K
34: R21 Employee Benefit Plans HTML 24K
35: R22 Commitments and Contingencies HTML 31K
36: R23 Related Party Transactions HTML 32K
37: R24 Subsequent Events HTML 23K
38: R25 Summary of Significant Accounting Policies HTML 125K
(Policies)
39: R26 Summary of Significant Accounting Policies HTML 24K
(Tables)
40: R27 Accrued Expenses (Tables) HTML 26K
41: R28 Income Taxes (Tables) HTML 60K
42: R29 Share-Based Expense (Tables) HTML 115K
43: R30 Commitments and Contingencies (Tables) HTML 25K
44: R31 The Company (Details Narrative) HTML 26K
45: R32 Summary of Significant Accounting Policies HTML 27K
(Details)
46: R33 Summary of Significant Accounting Policies HTML 29K
(Details Narrative)
47: R34 Significant Strategic Collaborations (Details HTML 56K
Narrative)
48: R35 Licensing Arrangements (Details Narrative) HTML 54K
49: R36 Other Assets (Details Narrative) HTML 24K
50: R37 Accrued Expenses (Details) HTML 30K
51: R38 Fair Value Measurements (Details Narrative) HTML 25K
52: R39 Income Taxes (Details - Income by geographic HTML 37K
regions)
53: R40 Income Taxes (Details - Tax reconciliation) HTML 45K
54: R41 Income Taxes (Details - Deferred Tax Assets) HTML 60K
55: R42 Income Taxes (Details Narrative) HTML 40K
56: R43 Stockholders? Equity (Details Narrative) HTML 88K
57: R44 Share-Based Expense (Details - Share based HTML 27K
expense)
58: R45 Share-Based Expense (Details - Assumptions HTML 41K
Employee)
59: R46 Share-Based Expense (Details - Employee option HTML 70K
activity)
60: R47 Share-Based Expense (Details - Non-Vested employee HTML 46K
Option activity)
61: R48 Share-Based Expense (Details - Non-employee option HTML 70K
activity)
62: R49 Share-Based Expense (Details Narrative) HTML 67K
63: R50 Employee Benefit Plans (Details Narrative) HTML 25K
64: R51 Commitments and Contingencies (Details - Cash flow HTML 22K
Information)
65: R52 Commitments and Contingencies (Details Narrative) HTML 31K
66: R53 Related Party Transactions (Details Narrative) HTML 35K
68: XML IDEA XML File -- Filing Summary XML 120K
71: XML XBRL Instance -- xenetic_i10k-123123_htm XML 986K
67: EXCEL IDEA Workbook of Financial Report Info XLSX 120K
10: EX-101.CAL XBRL Calculations -- xbio-20231231_cal XML 118K
11: EX-101.DEF XBRL Definitions -- xbio-20231231_def XML 587K
12: EX-101.LAB XBRL Labels -- xbio-20231231_lab XML 871K
13: EX-101.PRE XBRL Presentations -- xbio-20231231_pre XML 779K
9: EX-101.SCH XBRL Schema -- xbio-20231231 XSD 116K
69: JSON XBRL Instance as JSON Data -- MetaLinks 409± 574K
70: ZIP XBRL Zipped Folder -- 0001683168-24-001594-xbrl Zip 402K
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, James Parslow, certify that:
| 1. | I have reviewed this annual report on Form 10-K of Xenetic Biosciences, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: March 21, 2024
By: /s/ James Parslow
Principal Financial Officer
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/21/24 | None on these Dates | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
